U.S. Markets closed

AbbVie stock ticks higher on FDA approval of psoriasis treatment

Wallace Witkowski

AbbVie Inc. shares ticked higher after the drug maker said Tuesday the Food and Drug Administration approved its psoriasis treatment Skyrizi. AbbVie shares rose 0.8% after hours, following a 0.7% rise to close the regular session at $78.66. In clinical trials, the drug cleared up skin by 90% in around 80% of patients and by 100% in just over half of patients, AbbVie said.